Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 21c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eagle Pharmaceuticals (EGRX) Announces Filing of TREAKISYM Rapid Infusion Liquid Formulation in Japan
May 10, 2021 6:45 AM EDTEagle Pharmaceuticals, Inc. (Eagle or the Company) (NASDAQ: EGRX) today announced that TREAKISYM RI (50ml) liquid formulation has been filed with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
The application is based on the results of clinical studies investigating the safety and pharmacokinetics of TREAKISYM RTD administered by... More
